Executive Director, Health Systems (Commercial)
At Madrigal, we are committed to transforming treatment for patients with non-alcoholic steatohepatitis (NASH). NASH will soon become the leading cause of liver transplantation in the U.S., but there are currently no approved medications to treat the disease.
Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Positive results from first of the the two Phase 3 clinical trials of resmetirom in NASH were announced in January 2022 and results from a second Phase 3 clinical trial are expected in Q4 2022. Resmetirom is on track to launch in the U.S. towards the end of 2023.
Madrigal has established its leadership position in NASH by staying true to its science-driven foundation and building a company culture based on collaboration and trust. Our team members are focused on delivering results for the benefit of investors, healthcare providers and, most importantly, patients. These values will remain central to Madrigal as the company grows and evolves its commercial capabilities to prepare for a potential first-to-market launch in NASH.
The Madrigal Story:
2004-2008: Madrigal founder Dr. Rebecca Taub studies THR-B agonism while working at Hoffmann-La Roche
2008: Madrigal predecessor company VIA Pharmaceuticals hires Dr. Taub and enters into a development agreement with Hoffmann-La Roche for resmetirom
2011: Madrigal is incorporated in Delaware and Ph 1 trial of resmetirom commences
2016: Ph 2 trial of resmetirom in NASH commences; Madrigal merges with Synta Pharmaceuticals and is listed on NASDAQ; and Dr. Paul Friedman named CEO and Rebecca Taub named CMO of Madrigal
2017-2018: Positive Ph 2 results in NASH help accelerate Madrigal’s growth
2019: Madrigal commences Ph 3 “MAESTRO” program for resmetirom
2020: Madrigal hires Remy Sukhija as Chief Commercial Officer and begins building its commercial organization
2021: Madrigal continues to expand executive team
2021-2022: Positive Phase 3 MAESTRO-NAFLD-1 resmetirom data announced
Madrigal’s commercial team
Madrigal’s commercial team is in constant pursuit of excellence in what we do and the way we show-up, every day. Conducting our business in an honest and transparent fashion is of prime importance to us. We have a “business owner” mentality as we feel the awesome responsibility to do right by the opportunity we have been given to bring a potentially revolutionary therapy to patients and their healthcare providers. It is essential for each one us on the commercial team to have deep and up-to-date knowledge of resmetirom program and developments in NASH as we prepare to answer the needs of the patients and physicians we hope to serve with approval and launch of resmetirom in the U.S.
Opportunity and Summary of Position:
Resmetirom is expected to launch in the U.S. as a “specialty drug” with a supporting closed speciality pharmacy distribution model. We expect there may be 50 to 100 Health Systems (or Intergrated Delivery Network) that may have intent and ability to control access to pharmaceuticals including resmetirom (when approved) among their network of NASH specialists (Hepatologsits, select Gastroenterologists, and select Endocrinologists). Therefore it is critically important for Madrigal to build relationships with key decisions makers at these Health Systems and deliver novel value propositions that allows for appropriate use of resmetirom by NASH specialists at these Health Systems. This role will lead development of Madrigal’s business strategy for Health Systems, partner with Medical Affairs and Market Access to create novel value propositions and deliver them to Health Systems via a team of Key Account Managers in partnership with field personnel from Medical Affairs and Market Access. Executive Director, Health Systems Management will report directly to Chief Commercial Officer, Madrigal Pharma.
Develop and maintain deep understanding of NASH disease state, resmetirom clinical data and commercialization strategy; and while leading by example, assure the Health Systems Management team acquires and maintains requisite level of knowledge of NASH disease state and resmetirom clinical data.
Building on market sizing and targeting analysis, develop Madrigal’s strategy for prioritized Health Systems.
Understand prioritized Health Systems needs relative to NASH and partner with Medical Affairs and Market Access to create novel value propositions to answer the needs of prioritized Health Systems.
Build strong business relationships with key decision makers at prioritized Health Systems
Partner with Medical Affairs, Market Access and Commercial Strategy & Insights teams to build novel value propositions that answer the needs of prioritized Health Systems.
Partner with VP, Sales to assure Madrigal sales force has sufficient access to NASH specialists in prioritized Health Systems’ networks
Partner with Market Access, HEOR and Finance team members for financial planning and contracting, if needed to answer the needs of any prioritized Health Systems
Recruit a high-caliber Health Systems Manager team (~4 to 8 FTE) based on the output of market sizing and targeting analysis and in line with prioritized competencies
Partner with Marketing and Market Access to assure the Key Account Managers have collateral they need for discussions with customers at prioritized Health Systems
Think strategically about future needs of prioritized customers and evolve value propositions to meet future needs
Partner with CCO and General Counsel to develop policy/SOP for Health Systems Management team teams’ interactions and information exchange with other field-based roles (for e.g., MSLs, Sales, Market Access Account Executives, etc.) and HQ-based roles (for e.g., Commercial Strategy & Insights)
Expect to spend ~80% of work time dedicated to meeting with customers, hiring, leading and managing Health Systems Managers and ~20% involved in HQ matters during launch year.
Consistently deliver on business goals and objectives while ensuring that the Health Systems Management team operates with the highest compliance and integrity standards
Qualifications and Skills
Demonstrated Health Systems leadership and performance in support of a drug launch
Strong business acumen, excellent planning skills and demonstrated ability to organize and lead work of internal partners in Medical Affairs, Market Access, Commercial Strategy & Insights and Marketing
Demonstrated track record of building teams from ground-up
Strong collaborator that has a strong customer focus approach
Attention to detail and the ability to work individually, within a multi-disciplinary team, as well as with external partners and vendors
Ability to make quality decisions with less than complete information and demonstrated ability to communicate well with other commercial and medical functions
10+ years related experience in the biopharma industry with a proven, consistent history of high performance in a broad range of leadership roles of increasing responsibility
5+ years of progressive Health Systems leadership experience with demonstrated results with National accountability (e.g., payer account management, organize provider account management)
BA/BS degree required. Advanced Degree in Business, Marketing or Life Sciences preferred
Significant product launch experience in Health Systems roles
Demonstrates exceptional leadership, management, and communication skills to inspire teams to achieve high levels of performance
Strong executive presence with the ability to set vision and strategy for Health Systems Management
Strong understanding of payer environment and utilization management measures that impact HCP prescribing requirements and patient access
Strong history of creating and leading high-performance teams and creating a culture of continuous improvement, high engagement, performance and accountability
Experience working with all levels of management and consulting with key business stakeholders, with an ability to influence for greater outcomes
Possesses strong written and verbal communication skills
Excitement about the vision and mission of Madrigal
An attractive compensation package will be offered to the successful candidate. It will include a competitive base salary and incentive bonus. A benefits package customary to the position will also be provided including 401k match, medical and dental.
Madrigal is an Equal Opportunity Employer and will judge all applicants based on their qualifications for the job, without regard to race, color, sex, religion, national origin, age, disability, sexual orientation, gender identity, protected veteran, disability status or any other characteristics protected by applicable federal, state or local law.
Unsolicited resumes from agencies should not be forwarded to Madrigal. Madrigal will not be responsible for any fees arising from the use of resumes through this source. Madrigal will only pay a fee to agencies if a formal agreement between Madrigal and the agency has been established.
Proof of full vaccination against COVID-19 prior to start date required.